DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
← catalyst calendarNCT07358078 · readout in 1,526 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-09 | actual | When the study began enrolling |
| Primary completion | 2030-10-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloidosis With Cardiomyopathy
Primary outcomes
what the primary-completion date above is the date OFNew York Heart Association (NYHA) Class
measured From time of ATTR-CM diagnosis up to 5 years
Outpatient Diuretic Intensification
measured From time of enrollment for up to 5 years
Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score
measured From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Kansas City Cardiomyopathy Questionnaire (KCCQ)
measured From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Patient Global Impressions - Change (PGI-C)
measured From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Patient Global Impressions - Severity (PGI-S);
measured From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9)
measured From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed